RBC Capital Maintains Sector Perform on CRISPR Therapeutics, Raises Price Target to $66
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has maintained a 'Sector Perform' rating on CRISPR Therapeutics (NASDAQ:CRSP) and increased the price target from $57 to $66.
February 22, 2024 | 5:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has maintained its 'Sector Perform' rating on CRISPR Therapeutics and raised its price target from $57 to $66.
The increase in price target by RBC Capital suggests a positive outlook on CRISPR Therapeutics' stock, likely due to anticipated performance or favorable market conditions. This adjustment can lead to increased investor confidence and potential short-term price appreciation.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100